A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
Business letters: October 20
18 October 2013
YOU say that turning university science projects into big companies is mostly impossible (“Imperial needs to pick more winners”, last week). Yet the acquisition of Spirogen by Astra Zeneca for $440m (£272m) last week shows that substantial returns to investors are possible from university research.
Read: The Sunday Times